---
layout: default
title: Mecobalamin
parent: 僅模型預測 (L5)
nav_order: 401
evidence_level: L5
indication_count: 3
---

# Mecobalamin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **3** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Mecobalamin: From Unrecorded Original Indication to Sclerosing Cholangitis

## One-Sentence Summary

> No original indication data is on file for mecobalamin in this evidence pack, and the drug is not currently marketed in Saudi Arabia.
> The TxGNN model predicts a possible association with **Sclerosing Cholangitis**,
> but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a computational signal only, with no direct clinical or mechanistic evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in evidence pack (no original indications on file) |
| Predicted New Indication | Sclerosing Cholangitis |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for mecobalamin is not available as a structured field in this evidence pack. However, the model's own rationale notes that mecobalamin's known biochemical role is as a coenzyme for methionine synthase, involved in homocysteine metabolism.

Sclerosing cholangitis is primarily an autoimmune/cholestatic biliary disease, driven by bile duct fibrosis and immune-mediated inflammation. There is no established direct overlap between methionine synthase/homocysteine metabolism and the immune-inflammatory pathways underlying bile duct injury. The only plausible connection is an indirect one — via homocysteine and oxidative stress — which the evidence pack itself characterizes as speculative, without direct molecular mechanism support.

Two additional candidates were also predicted (multiple endocrine neoplasia, rank 2; bone Paget disease, rank 3), both similarly flagged as biologically indirect associations rather than mechanistically grounded links. All three predictions currently rest on TxGNN model output alone, with no corroborating trials or literature.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Mecobalamin is not currently marketed in Saudi Arabia — 0 authorizations are on file, so no product/license table is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA package insert warnings/contraindications are flagged as a **Blocking** data gap (DG001) — this evidence pack cannot yet support an S1 safety pre-assessment for mecobalamin.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (Sclerosing Cholangitis) is supported only by TxGNN model output (L5, no clinical trials or literature), and a blocking data gap (missing TFDA label/contraindication data) prevents any safety pre-assessment. The drug is also not currently marketed in Saudi Arabia.

**To proceed, the following is needed:**
- TFDA/regulatory package insert (warnings, contraindications) — currently blocking
- Confirmed mechanism of action data from DrugBank
- Confirmed original indication(s) for mecobalamin
- Disease-specific clinical trial or literature search focused on sclerosing cholangitis (current searches returned zero results)
- Re-evaluation of the two lower-ranked candidates (multiple endocrine neoplasia, bone Paget disease) if pursued further — both currently show equally weak evidence
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

